Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Tax Provisions (2016 - 2025)

United Therapeutics' Tax Provisions history spans 17 years, with the latest figure at $79.7 million for Q4 2025.

  • For Q4 2025, Tax Provisions fell 16.28% year-over-year to $79.7 million; the TTM value through Dec 2025 reached $379.2 million, up 10.26%, while the annual FY2025 figure was $379.2 million, 10.26% up from the prior year.
  • Tax Provisions for Q4 2025 was $79.7 million at United Therapeutics, down from $99.3 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $101.3 million in Q1 2025 and bottomed at $4.2 million in Q1 2021.
  • The 5-year median for Tax Provisions is $76.6 million (2023), against an average of $67.7 million.
  • The largest annual shift saw Tax Provisions crashed 87.61% in 2021 before it soared 1538.1% in 2022.
  • A 5-year view of Tax Provisions shows it stood at $28.3 million in 2021, then surged by 65.02% to $46.7 million in 2022, then surged by 67.67% to $78.3 million in 2023, then grew by 21.58% to $95.2 million in 2024, then fell by 16.28% to $79.7 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Tax Provisions are $79.7 million (Q4 2025), $99.3 million (Q3 2025), and $98.9 million (Q2 2025).